Go Pro
→ Shocking AI prediction from the “Billionaire Whisperer' (From Chaikin Analytics) (Ad)tc pixel Free BXP Stock Alerts

Beximco Pharmaceuticals (BXP) Competitors

Beximco Pharmaceuticals logo
Compare

BXP vs. VEC, ERGO, BMY, AMYT, and APH

Should you buy Beximco Pharmaceuticals stock or one of its competitors? Beximco Pharmaceuticals's main competitors and comparable companies include Vectura Group (VEC), Ergomed (ERGO), Bloomsbury Publishing (BMY), Amryt Pharma (AMYT), and Alliance Pharma (APH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Beximco Pharmaceuticals compare to Vectura Group?

Beximco Pharmaceuticals (LON:BXP) and Vectura Group (LON:VEC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 4.2% of Beximco Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Beximco Pharmaceuticals has higher revenue and earnings than Vectura Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A
Vectura Group£190.60M0.00N/A£20.10N/A

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than Vectura Group. MarketBeat recorded 1 mentions for Beximco Pharmaceuticals and 0 mentions for Vectura Group. Beximco Pharmaceuticals' average media sentiment score of 0.75 beat Vectura Group's score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Beximco Pharmaceuticals Positive
Vectura Group Neutral

Beximco Pharmaceuticals has a net margin of 16.76% compared to Vectura Group's net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 11.99% beat Vectura Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Vectura Group N/A N/A N/A

Summary

Beximco Pharmaceuticals beats Vectura Group on 9 of the 10 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Ergomed?

Beximco Pharmaceuticals (LON:BXP) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Beximco Pharmaceuticals has a net margin of 16.76% compared to Ergomed's net margin of 9.87%. Ergomed's return on equity of 18.08% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Ergomed 9.87%18.08%10.16%

0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 4.2% of Beximco Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Beximco Pharmaceuticals has higher revenue and earnings than Ergomed.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A
Ergomed£152.09M0.00£15M£0.29N/A

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for Beximco Pharmaceuticals and 0 mentions for Ergomed. Beximco Pharmaceuticals' average media sentiment score of 0.75 beat Ergomed's score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Beximco Pharmaceuticals Positive
Ergomed Neutral

Beximco Pharmaceuticals has a beta of 0.248, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Summary

Beximco Pharmaceuticals and Ergomed tied by winning 6 of the 12 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Bloomsbury Publishing?

Beximco Pharmaceuticals (LON:BXP) and Bloomsbury Publishing (LON:BMY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Beximco Pharmaceuticals has higher revenue and earnings than Bloomsbury Publishing. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A
Bloomsbury Publishing£325.90M1.54£37.37M£32.8018.98

Beximco Pharmaceuticals has a net margin of 16.76% compared to Bloomsbury Publishing's net margin of 8.28%. Bloomsbury Publishing's return on equity of 12.74% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Bloomsbury Publishing 8.28%12.74%7.82%

Bloomsbury Publishing has a consensus target price of GBX 800, suggesting a potential upside of 28.52%. Given Bloomsbury Publishing's stronger consensus rating and higher probable upside, analysts clearly believe Bloomsbury Publishing is more favorable than Beximco Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beximco Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Bloomsbury Publishing
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.2% of Bloomsbury Publishing shares are owned by institutional investors. 4.2% of Beximco Pharmaceuticals shares are owned by company insiders. Comparatively, 3.6% of Bloomsbury Publishing shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Beximco Pharmaceuticals has a beta of 0.248, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Bloomsbury Publishing has a beta of 0.418, indicating that its stock price is 58% less volatile than the broader market.

In the previous week, Bloomsbury Publishing had 3 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 4 mentions for Bloomsbury Publishing and 1 mentions for Beximco Pharmaceuticals. Beximco Pharmaceuticals' average media sentiment score of 0.75 beat Bloomsbury Publishing's score of -0.13 indicating that Beximco Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beximco Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bloomsbury Publishing
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Bloomsbury Publishing beats Beximco Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Amryt Pharma?

Beximco Pharmaceuticals (LON:BXP) and Amryt Pharma (LON:AMYT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. 4.2% of Beximco Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than Amryt Pharma. MarketBeat recorded 1 mentions for Beximco Pharmaceuticals and 0 mentions for Amryt Pharma. Beximco Pharmaceuticals' average media sentiment score of 0.75 beat Amryt Pharma's score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Beximco Pharmaceuticals Positive
Amryt Pharma Neutral

Beximco Pharmaceuticals has higher revenue and earnings than Amryt Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A
Amryt Pharma£210.24M0.00N/A-£33.00N/A

Beximco Pharmaceuticals has a net margin of 16.76% compared to Amryt Pharma's net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 11.99% beat Amryt Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Amryt Pharma N/A N/A N/A

Summary

Beximco Pharmaceuticals beats Amryt Pharma on 10 of the 10 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Alliance Pharma?

Alliance Pharma (LON:APH) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

66.3% of Alliance Pharma shares are held by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 12.0% of Alliance Pharma shares are held by company insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than Alliance Pharma. MarketBeat recorded 1 mentions for Beximco Pharmaceuticals and 0 mentions for Alliance Pharma. Beximco Pharmaceuticals' average media sentiment score of 0.75 beat Alliance Pharma's score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Alliance Pharma Neutral
Beximco Pharmaceuticals Positive

Alliance Pharma has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.248, suggesting that its share price is 75% less volatile than the broader market.

Beximco Pharmaceuticals has higher revenue and earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alliance Pharma£183.50M1.91-£33.65M-£6.20N/A
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A

Beximco Pharmaceuticals has a net margin of 16.76% compared to Alliance Pharma's net margin of -6.00%. Beximco Pharmaceuticals' return on equity of 11.99% beat Alliance Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Alliance Pharma-6.00% -5.04% 5.98%
Beximco Pharmaceuticals 16.76%11.99%6.97%

Summary

Beximco Pharmaceuticals beats Alliance Pharma on 9 of the 12 factors compared between the two stocks.

Get Beximco Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BXP vs. The Competition

Export
MetricBeximco PharmaceuticalsPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£267.67M£12.46B£7.16B£2.87B
Dividend Yield4.58%2.62%2.56%6.23%
P/E Ratio0.03799.74274.10366.83
Price / SalesN/A763.35656.0083,599.70
Price / CashN/A89.2577.0427.89
Price / BookN/A10.3910.336.33
Net Income£970.84B£2.85B£3.50B£5.89B
7 Day Performance-5.14%-3.70%-3.35%-0.69%
1 Month Performance10.66%0.78%-0.43%0.18%
1 Year Performance33.33%3.48%19.21%20.03%

Beximco Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BXP
Beximco Pharmaceuticals
N/AN/AN/A+33.3%£267.67M£53.93B0.035,500
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
BMY
Bloomsbury Publishing
2.8073 of 5 stars		GBX 624.92
-1.3%		GBX 800
+28.0%		+23.3%£503.65M£325.90M19.0534,300
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24MN/A290

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BXP) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Shocking AI prediction from the “Billionaire Whisperer"
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
The retirement income that answers “yes” when everything else says no
Todd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...
Eagle Publishing | Sponsoredtc pixel
My ‘one day’ retirement secret
TradeSmith's AI research team, backed by a $17 million investment and led by a former NSA codebreaker, built a...
TradeSmith | Sponsoredtc pixel